History of Value Creation

1920 - 1955

In 1920, Yasohachi Yamaguchi established Teikoku Hormone

manufacture and sales of hormone preparations based on the

unique idea of creating useful medicines from animal organs. Although the company experienced hardships such as the Great Kanto Earthquake, and the loss of its head office and

factory during the Second World War, it was rebuilt under a new organizational structure, and listed its shares on the

Tokyo Stock Exchange in 1955.

Research Institute. It began the research, development,

Took our first step as a pharmaceutical company

Since our founding in 1920 as a pioneer in hormone preparations, we have unerringly continued on our journey, while always keeping in mind our essential mission as a company that is directly linked to life and health. In 2021, we transitioned to a holding company structure, and took a new step toward the next 100 years. We will continue to respond to the changing times and environment, and contribute to society as we evolve into a total healthcare company.

1955 - 2005

Became a company that makes wide-ranging contributions to society

After the postwar reconstruction period, the company worked to modernize its management through organizational reforms, expansion of its sales and production systems, reorganization of its research functions, and reinforcement of its advertising activities. In addition to entering the field of veterinary pharmaceuticals, the company also strived to diversify its business and work toward corporate growth in the midst of an era of rapid economic growth.





2005 - 2021

Formation of ASKA Pharmaceutical Co., Ltd.

In 2005, ASKA Pharmaceutical Co., Ltd. was established to develop and market new drugs, specializing in the three priority areas of internal medicine, obstetrics and gynecology (Ob/Gyn), and urology with the aim of becoming a competitive specialty pharma company. The company took on challenges for the next stage, such as strengthening efforts for generic drugs that meet the needs of the times.





1986

Enforcement of Act on Equal Opportunity and

Treatment between

Men and Women

in Employment

24,390



1992

Enforcement of Childcare Leave Act*

* Currently Act on the Welfare of Workers Who

Including Child Care and Family Care Leave

1990

Take Care of Children or Other Family Members





FY2023

2021 -

Aim for further growth

ASKA Pharmaceutical Holdings' Medium-Term Managemen

Plan 2025 was launched in 2021. In conjunction with the shift to a holding company structure, the Company not only

aims to build a flexible organization that is capable of swift

decision-making, but also to achieve further sustainable growth for the entire Group by further strengthening its

governance structure.

¥62,843 million

2022 Enforcement of Revised Act on the Promotion of Women's Active Engagement in Professional Life





2016

Enforcement of Act on the Promotion of Women's Active Engagement in Professional Life







2020

2000 2010 Net sales

23,537

Consolidated accounting (Merged with Grelan Pharmaceutical Co., Ltd. in October 2005)

1945 Women's suffrage in Japan

Net sales (Millions of ven)

0.038 4.115 (FY) 1920 1929 1940 Line item Sales profit

Six-month settlement period (Two six-month periods were combined for the data for years 1930-1937)

Eight-month settlement period

Product proceeds

Twenty-four-month Four-month settlement period

294

1950

Product proceeds

Ten-month settlement period

940

1960

Net sales

4,929

1970

Six-month settlement period

1975 International Women's Year

12,409

1980

ASKA HD REPORT 2024